Orchestra BioMed Holdings Inc (OBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.08+7.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Orchestra BioMed is developing treatments for heart diseases. It expects revenue of at least $11 million in 2026 and $30 million in 2025. The company recently gained $21 million from an acquisition. These show potential for recovery and growth.
The company is still losing money and faces a sharp recent selloff. Analysts expect revenue to drop nearly 93% next year. Its free cash flow yield is negative and valuation is weak compared to peers.
The price is about 40% below our fair value near $6.5. The market expects revenue to fall sharply by about 93%, which we view as too pessimistic.
Breaks if: cash proceeds from acquisition fall materially short of $21 million
Breaks if: annual revenue falls below $11 million in FY26
Breaks if: annual revenue falls below $30 million in FY25
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as OBIO operates in a high-miss-rate industry and is currently loss-making. The thesis is in a cautious state, reflecting recent performance that is better than many peers but still carries elevated risks.
The market currently prices OBIO as cheap compared to its peers, with an expectations gap indicating that investors may not fully believe in its recovery potential. There is a low level of fragility, suggesting that the stock is not overly sensitive to negative news at this time.
Fundamentals are likely to remain neutral in the near term, as the company has stable management but is still loss-making. The probability of missing earnings is relatively low, but the industry is known for erratic performance, which adds uncertainty.
The future performance of OBIO hinges on several factors, including guidance updates from management and the broader healthcare sector's performance. Positive earnings from key sector players could provide momentum, while any cuts to guidance or worsening economic indicators could negatively impact sentiment.
Over the next 1 to 3 years, OBIO's performance will depend on its ability to navigate industry challenges and leverage sector momentum. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.